Literature DB >> 21821714

Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS).

Can-Lan Sun1, Liton Francisco, K Scott Baker, Daniel J Weisdorf, Stephen J Forman, Smita Bhatia.   

Abstract

Little information exists regarding long-term psychological health of hematopoietic cell transplantation (HCT) survivors. Using resources offered by the Bone Marrow Transplant Survivor Study (BMTSS), we evaluated adverse psychological outcomes in 1065 long-term HCT survivors and a healthy comparison group composed of siblings. Psychological health status was evaluated using the Brief Symptom Inventory-18. Twenty-two percent of the HCT survivors reported adverse psychological outcomes, compared with 8% of the siblings. Exposure to prednisone was associated with psychological distress across all domains (anxiety, depression, and somatic distress). Fifteen percent of the HCT survivors reported somatic distress, representing an almost 3-fold higher risk comparing to siblings. Among survivors, in addition to low annual household income and self-reported poor health, having severe/life-threatening conditions and presence of active chronic GVHD were associated with a 2-fold increased risk for somatic distress. Seven percent of the HCT survivors expressed suicidal ideation; patients with higher scores on depression subscale were most vulnerable. This study demonstrates that somatic distress is the biggest challenge faced by survivors long after HCT. These results identify vulnerable subpopulations and provide patients, families, and healthcare providers with necessary information to plan for post-HCT needs many years after HCT.

Entities:  

Mesh:

Year:  2011        PMID: 21821714      PMCID: PMC3208286          DOI: 10.1182/blood-2011-04-348730

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Quality of life and factors related to perceived satisfaction with quality of life after allogeneic bone marrow transplantation.

Authors:  H Heinonen; L Volin; A Uutela; M Zevon; C Barrick; T Ruutu
Journal:  Ann Hematol       Date:  2001-03       Impact factor: 3.673

2.  Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients.

Authors:  N E Bush; G W Donaldson; M H Haberman; R Dacanay; K M Sullivan
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

3.  A new psychosocial screening instrument for use with cancer patients.

Authors:  J Zabora; K BrintzenhofeSzoc; P Jacobsen; B Curbow; S Piantadosi; C Hooker; A Owens; L Derogatis
Journal:  Psychosomatics       Date:  2001 May-Jun       Impact factor: 2.386

Review 4.  The corticosteroid receptor hypothesis of depression.

Authors:  F Holsboer
Journal:  Neuropsychopharmacology       Date:  2000-11       Impact factor: 7.853

5.  Quality of life in 244 recipients of allogeneic bone marrow transplantation.

Authors:  S Chiodi; S Spinelli; G Ravera; A R Petti; M T Van Lint; T Lamparelli; F Gualandi; D Occhini; N Mordini; G Berisso; S Bregante; F Frassoni; A Bacigalupo
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

6.  The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation.

Authors:  M J Hjermstad; J H Loge; S A Evensen; S O Kvaløy; P M Fayers; S Kaasa
Journal:  Bone Marrow Transplant       Date:  1999-12       Impact factor: 5.483

7.  Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation.

Authors:  Jesús M Prieto; Jordi Blanch; Jorge Atala; Enric Carreras; Montserrat Rovira; Esteve Cirera; Cristóbal Gastó
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

8.  Longitudinal study of adaptation to the stress of bone marrow transplantation.

Authors:  B L Fife; G A Huster; K G Cornetta; V N Kennedy; L P Akard; E R Broun
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

9.  Recovery after stem-cell transplantation for hematologic diseases.

Authors:  S J Lee; D Fairclough; S K Parsons; R J Soiffer; D C Fisher; R L Schlossman; J H Antin; J C Weeks
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

10.  Exogenous corticosteroids and major depression in the general population.

Authors:  S B Patten
Journal:  J Psychosom Res       Date:  2000-12       Impact factor: 3.006

View more
  40 in total

1.  An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation.

Authors:  Karen L Syrjala; Jean C Yi; Samantha B Artherholt; Joan M Romano; Marie-Laure Crouch; Allison S Fiscalini; Mark T Hegel; Mary E D Flowers; Paul J Martin; Wendy M Leisenring
Journal:  J Cancer Surviv       Date:  2018-05-05       Impact factor: 4.442

2.  Risk factors for depression in patients undergoing hematopoietic cell transplantation.

Authors:  Samantha B Artherholt; Fangxin Hong; Donna L Berry; Jesse R Fann
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-18       Impact factor: 5.742

Review 3.  Anxiety, depression, and mental health-related quality of life in survivors of pediatric allogeneic hematopoietic stem cell transplantation: a systematic review.

Authors:  Tal Schechter; Jason D Pole; Giancarlo Di Giuseppe; Nirav Thacker
Journal:  Bone Marrow Transplant       Date:  2020-01-24       Impact factor: 5.483

Review 4.  Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care.

Authors:  Minoo Battiwalla; André Tichelli; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-03       Impact factor: 5.742

5.  Survivor and Clinician Assessment of Survivorship Care Plans for Hematopoietic Stem Cell Transplantation Patients: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.

Authors:  Colleen M Morken; Amye J Tevaarwerk; Amanda K Swiecichowski; James E Haine; Zachary T Williams; Kirsten Norslien; Natalia Arroyo; Xiao Zhang; Bethaney Campbell; Eneida A Mendonca; Mark B Juckett; Mary E Sesto
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-11       Impact factor: 5.742

6.  Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD.

Authors:  Ludovic Belle; Vivian Zhou; Kara L Stuhr; Margaret Beatka; Emily M Siebers; Jennifer M Knight; Michael W Lawlor; Casey Weaver; Misato Hashizume; Cecilia J Hillard; William R Drobyski
Journal:  JCI Insight       Date:  2017-07-20

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report.

Authors:  Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-19       Impact factor: 5.742

8.  Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study.

Authors:  Can-Lan Sun; John H Kersey; Liton Francisco; Saro H Armenian; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-10       Impact factor: 5.742

9.  Late effects and healthcare needs of survivors of allogeneic stem cell transplantation: a qualitative study.

Authors:  Jessica P Hwang; Aimee K Roundtree; Sergio A Giralt; Maria Suarez-Almazor
Journal:  BMJ Support Palliat Care       Date:  2012-08-03       Impact factor: 3.568

10.  Resilience, health, and quality of life among long-term survivors of hematopoietic cell transplantation.

Authors:  Abby R Rosenberg; Karen L Syrjala; Paul J Martin; Mary E Flowers; Paul A Carpenter; Rachel B Salit; K Scott Baker; Stephanie J Lee
Journal:  Cancer       Date:  2015-08-19       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.